AIGH Capital Management LLC Has $16.68 Million Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

AIGH Capital Management LLC trimmed its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 22.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,385,389 shares of the company’s stock after selling 397,101 shares during the period. Delcath Systems accounts for 5.2% of AIGH Capital Management LLC’s portfolio, making the stock its 6th largest holding. AIGH Capital Management LLC owned approximately 4.33% of Delcath Systems worth $16,680,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. EntryPoint Capital LLC purchased a new stake in Delcath Systems in the 4th quarter worth about $299,000. Simplify Asset Management Inc. bought a new stake in shares of Delcath Systems during the 4th quarter worth approximately $205,000. Quantbot Technologies LP bought a new stake in shares of Delcath Systems during the 4th quarter worth approximately $66,000. Charles Schwab Investment Management Inc. bought a new position in Delcath Systems in the 4th quarter valued at $156,000. Finally, Private Advisor Group LLC purchased a new stake in Delcath Systems in the fourth quarter worth $153,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Stock Down 1.9 %

Shares of NASDAQ:DCTH opened at $13.15 on Friday. Delcath Systems, Inc. has a 52-week low of $4.26 and a 52-week high of $16.97. The business has a fifty day moving average of $14.59 and a two-hundred day moving average of $12.03. The stock has a market cap of $439.25 million, a P/E ratio of -9.74 and a beta of 0.82.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The business had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share. On average, equities analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DCTH shares. Craig Hallum boosted their price target on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. HC Wainwright lifted their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.